NCT05159700View on ClinicalTrials.gov

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

July 17, 2024

Study Completion Date

October 12, 2024

Conditions
Advanced Solid TumorAdvanced Solid Malignancies
Interventions
DRUG

PRJ1-3024

PRJ1-3024 is provided as capsules and is administered orally once a day.

Trial Locations (6)

21073

Christ Hospital, Cincinnati

22031

NEXT Oncology, Fairfax

32827

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando

73301

NEXT Oncology, Austin

78229

Mays Cancer Center, San Antonio

80218

Sarah Cannon Research Institute at HealthONE, Denver

All Listed Sponsors
lead

Zhuhai Yufan Biotechnologies Co., Ltd

INDUSTRY